We are live on ! Find out more
LP

LMR Partners Portfolio holdings

AUM $45.4B
1-Year Est. Return 60.68%
This Fund
S&P 500
This Quarter Est. Return
+23.27%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$11.9B
AUM Growth
-$665M
Cap. Flow
-$2.07B
Cap. Flow %
-17.42%
Top 10 Hldgs %
29.25%
Holding
1,790
New
534
Increased
200
Reduced
243
Closed
613

Top Sells

Rank Stock Value
1
TSM icon
TSMC
TSM
+$107M
2
GSK icon
GSK
GSK
+$58.9M
3
AVGO icon
Broadcom
AVGO
+$54M
4
UL icon
Unilever
UL
+$54M
5
MRVL icon
Marvell Technology
MRVL
+$48.3M

Sector Composition

Rank Sector Weight
1 Technology 11.5%
2 Communication Services 3.61%
3 Financials 3.6%
4 Healthcare 3.01%
5 Consumer Discretionary 1.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AAL icon
251
PUT
American Airlines Group
AAL
$9.9B
$8.18M 0.07%
469,200
VIAV icon
252
Viavi Solutions
VIAV
$9.42B
$8.08M 0.07%
+800,000
New +$7.9M
TDACU
253
Translational Development Acquisition Corp Units
TDACU
$8.02M 0.07%
+800,000
New +$8.01M
DRDBU
254
Roman DBDR Acquisition Corp II Unit
DRDBU
$7.98M 0.07%
+800,000
New +$7.96M
EDR
255
PUT
DELISTED
Endeavor Group Holdings, Inc.
EDR
$7.88M 0.07%
+251,700
New +$7.49M
MTTR
256
PUT
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
$7.66M 0.06%
+1,616,200
New +$7.67M
PWR icon
257
CALL
Quanta Services
PWR
$93B
$7.65M 0.06%
24,200
VZ icon
258
CALL
Verizon
VZ
$198B
$7.64M 0.06%
191,100
+113,300
+146% +$4.78M
ROIV icon
259
Roivant Sciences
ROIV
$25B
$7.62M 0.06%
644,445
-200,000
-24% -$2.36M
ARM icon
260
CALL
Arm
ARM
$285B
$7.61M 0.06%
61,700
-3,900
-6% -$550K
SUM
261
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
$7.59M 0.06%
+150,001
New +$7.01M
BMY icon
262
Bristol-Myers Squibb
BMY
$128B
$7.48M 0.06%
132,167
-127,795
-49% -$7.14M
PSO icon
263
Pearson
PSO
$10.1B
$7.47M 0.06%
463,456
BERY
264
DELISTED
Berry Global Group, Inc.
BERY
$7.44M 0.06%
+115,000
New +$7.59M
ADI icon
265
Analog Devices
ADI
$181B
$7.44M 0.06%
35,000
+30,414
+663% +$6.72M
UNH icon
266
PUT
UnitedHealth
UNH
$379B
$7.39M 0.06%
14,600
+4,100
+39% +$2.33M
EWZ icon
267
CALL
iShares MSCI Brazil ETF
EWZ
$9.07B
$7.32M 0.06%
+325,000
New +$8.7M
NBIS
268
Nebius Group N.V.
NBIS
$47.7B
$7.27M 0.06%
+262,389
New +$6.4M
BSII
269
DELISTED
Black Spade Acquisition II Co Class A Ordinary Share
BSII
$7.2M 0.06%
+725,000
New +$7.17M
SMCI icon
270
CALL
Super Micro Computer
SMCI
$19.3B
$7.14M 0.06%
+234,300
New +$8.52M
SW
271
Smurfit Westrock
SW
$26.3B
$7.1M 0.06%
+131,840
New +$6.72M
LUXE
272
LuxExperience B.V.
LUXE
$1.14B
$7.1M 0.06%
1,000,000
RUMBW
273
RUM Group Inc Warrant
RUMBW
$13M
$7.1M 0.06%
+1,414,091
New +$3.07M
VCIC
274
DELISTED
Vine Hill Capital Investment Corp
VCIC
$7.04M 0.06%
+700,000
New +$7M
MASI
275
DELISTED
Masimo
MASI
$7.02M 0.06%
+42,448
New +$6.7M

Similar funds

LMR Partners's Q4 2024 Portfolio in Review

As of Q4 2024, LMR Partners held 1,790 positions worth $11.9B, down 5.3% from $12.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

LMR Partners withdrew a net $2.07B in Q4 2024, closing 613 positions and reducing 243 holdings. Its most notable exit was Unilever, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 10% a quarter earlier, followed by Communication Services and Financials.

Against the trend, LMR Partners opened a new position in Vertex Pharmaceuticals worth $37.8M.

  • LMR Partners's largest Q4 2024 buy was Vertex Pharmaceuticals: 93,801 shares worth $37.8M.
  • LMR Partners added most to State Street SPDR S&P 500 ETF Trust in Q4 2024, an estimated $472M increase.
  • LMR Partners's biggest Q4 2024 reduction was TSMC, cutting an estimated $107M.
  • LMR Partners fully exited Unilever in Q4 2024, selling an estimated $54M.
  • LMR Partners's ten largest holdings make up 29% of its $11.9B portfolio in Q4 2024.
  • LMR Partners opened 534 new positions and closed 613 in Q4 2024.
  • LMR Partners's portfolio value fell 5.3% quarter-over-quarter to $11.9B.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.